Nasal polyps are soft, noncancerous growths on the lining of the nose or sinuses. These growths, while painless, can cause blockages that prevent the sinuses from draining properly. This can make it ...

Nasal polyps are painless, teardrop-shaped growths that form in your nose or sinuses. They’re most common where the sinuses near your eyes and cheekbones drain into your nose. Nasal polyps are not ...

A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal ...

Please provide your email address to receive an email when new articles are posted on . Three currently available type 2 biologics approved for asthma appeared effective in treating chronic ...

Nasal polyp development, treatment, and recurrence were topics up for discussion in this year’s most popular nasal polyps–related content. Nasal polyp development, treatment, and recurrence, as well ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections cut total nasal polyps score by ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

Nasal polyps are common, affecting up to 4% of the general population, and can affect quality of life, but are usually benign. However, a new study suggests that when they occur in older patients (≥ ...

Competition among biologics that target inflammatory respiratory disease is heating up even further. On Thursday, AstraZeneca said its Fasenra, used in tandem with standard steroids, significantly ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Prevalence of type 2 inflammation ranged from 64.2% to ...